Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Plasma
ACTH
and/or corticosterone levels were measured in conscious rats 30 min after subcutaneous administration of arginine vasopressin (AVP),
oxytocin
(OT) and various analogs with a large range of activity on the vasopressor (V1), antidiuretic (V2) or oxytocic receptors. The comparison of their dose-response curves indicated that two different mechanisms are involved in the release of
ACTH
by neurohypophysial peptides and their analogs. AVP itself and a specific vasopressor agonist (Phe2, Orn8, OT) displayed a similar, high slope dose-response curve. Non-vasopressor analogs, such as dDAVP were characterized by a low slope dose-response curve. Furthermore, dDAVP potentiated CRF and neither its own
ACTH
-releasing action nor its potentiation of CRF were sensitive to previous VI- or V2-receptor blockade. These results, together with other available data, are interpreted as indicative of the existence of two mechanisms of action for
ACTH
release by AVP and its analogs in vivo: an indirect action via endogenous CRF release, mediated by a VI receptor mechanism, and a direct action on the pituitary, shared by dDAVP and other non-vasopressor analogs, with receptor characteristics different to both the V1 and the V2 classical types.
...
PMID:Analysis of the dual mechanism of ACTH release by arginine vasopressin and its analogs in conscious rats. 300 41
Recent studies have demonstrated that
oxytocin
(OT) is released during certain stresses and that OT can potentiate the activity of CRF in vitro. To better define the role of OT during stress, the effect of injections of anti-OT antiserum on stress-induced corticotropin (
ACTH
) secretion was studied in vivo. A dose of antiserum which completely neutralized the increase in plasma OT levels during tail-hang stress caused a 59% decrease in plasma
ACTH
concentrations (P less than 0.005). The data support a physiologic role for OT in the regulation of
ACTH
secretion.
...
PMID:Immunoneutralization of oxytocin attenuates stress-induced corticotropin secretion in the rat. 300 19
Neuropeptides and biogenic amines known to be present in neurons or afferent terminals in the paraventricular nucleus (PVH), supraoptic nucleus (SON) and/or lateral hypothalamus (LH) were added to small areas of these structures obtained by micropuncture and cyclic adenosine monophosphate (cAMP) levels were measured. cAMP accumulation occurred in PVH, SON and LH in response to neuropeptides of the secretin family, such as vasoactive intestinal peptide (VIP) and in response to catecholamines. Bradykinin, alpha-melanocyte-stimulating (alpha-MSH), luteinizing hormone-releasing hormone (LH-RH),
oxytocin
and carbamylcholine stimulated cAMP accumulation selectively in one or two of the above structures. Glucagon, cholecystokinin (CCK), somatostatin (SRIF), corticotropin-releasing factor (CRF), thyrotropin-releasing hormone (TRH), adrenocorticotropin (
ACTH
), melanocyte-stimulating hormone (MSH), methionine enkephalin (Met-Enk), beta-endorphin, neurotensin, bombesin and angiotensin II did not effect cAMP levels while leucine enkephalin (Leu-Enk), arginine vasopressin and gamma-aminobutyric acid (GABA) elicited regionally selective decreases in basal levels of cAMP. When interactions between some of these compounds were measured, VIP and norepinephrine exerted a more than additive effect on cAMP elevation in the PVH, while the effect on cAMP of the SON and LH was additive.
...
PMID:Interaction of neuropeptides and biogenic amines on cyclic adenosine monophosphate accumulation in hypothalamic nuclei. 300 57
The most examined tumor markers in lung cancer patients are CEA, hormonal peptides, and some neurogenic enzymes in small cell carcinoma. Calcitonin,
ACTH
, ADH, CEA,
neurophysin
,
oxytocin
, beta-endorphin, neuron-specific enolase, and CK BB are elevated in serum specimens in 25-75% of cases of small cell carcinoma. The level of these markers is related to the stage of the disease in groups of patients; elevated pretreatment levels decrease with tumor regression. Marker levels are not valid in defining the tumor load and the presence of disease in the individual patient. It has not yet been documented that the markers can be used for clinical decisions on antineoplastic therapy. A recent development is the finding that measurement of CSF and plasma concentrations of ADH, calcitonin, CK BB, bombesin, and neuron-specific enolase may contribute in the diagnosis of CNS metastases including meningeal carcinomatosis.
...
PMID:Tumor markers in patients with lung cancer. 300 40
The role of
oxytocin
(OT) in regulating stress-induced
ACTH
secretion was investigated by immunoneutralization of endogenous OT with an antiserum raised against synthetic OT. Rats were subjected to one of three stresses: novel environment, tail-hang, or ether. In otherwise untreated rats,
ACTH
levels rose at least 3-fold in response to all three stresses whereas OT levels increased only in response to tail-hang and ether. Injection of a highly specific antiserum to OT 60 min before the experiment inhibited the
ACTH
response to tail-hang and ether by 64 and 56%, respectively, but had no effect on the
ACTH
response to novel environment stress. The data support a physiologic role for OT in the control of
ACTH
secretion but suggest that it is not until OT levels rise in response to stress that the effects of OT are expressed.
...
PMID:Stress-specific modulation of ACTH secretion by oxytocin. 301 Jan 55
A slight but significant natriuretic action of 1-24
ACTH
was confirmed both in trained conscious nonhydrated rats and in anaesthetized rats with sustained water diuresis. This action was compared with a strongly effective
oxytocin
analogue, nacartocin.
...
PMID:The natriuretic effect of 1-24 ACTH in rats: a comparison with the natriuretic oxytocin analogue nacartocin. 301 Mar 51
Oxytocin
(OT) generally has a stimulatory effect on
ACTH
secretion both in vitro and in vivo. As part of a study of
ACTH
-releasing factors in hypophysial portal blood, the effects of i.v. OT administration on plasma
ACTH
levels were tested in urethane-anesthetized rats. Surprisingly, i.v. injection of 10 micrograms OT lowered plasma
ACTH
levels by about 35% (P less than 0.01). It was reasoned that this paradoxical inhibition of
ACTH
secretion by OT might be mediated by inhibition of the unusually high rate of peripheral catecholamine secretion in this model. Measurement of plasma catecholamines before and after i.v. administration of 10 micrograms OT revealed a 53% inhibition of EPI (P less than 0.01) and 43% inhibition of NE (P less than 0.05). Administration of the beta-adrenergic antagonist propranolol (400 micrograms) 15 min before the beginning of the experiment completely blocked the inhibitory effects of OT on
ACTH
secretion and in fact unmasked the stimulatory effects of OT normally seen in conscious animals and in vitro. Superfused bisected adrenal glands exposed to 10(-6) M OT for 10 min secreted more than 30% less EPI and NE than control adrenals suggesting that the inhibition of EPI and NE secretion by OT in vivo occurs, at least in part, directly at the level of the adrenal. The data support the hypothesis that peripheral catecholamines may at times be directly involved in the control of
ACTH
secretion and also suggest that OT, which has recently been identified in the adrenal medulla, may have important paracrine functions in the regulation of adrenal catecholamine secretion.
...
PMID:Oxytocin inhibits ACTH and peripheral catecholamine secretion in the urethane-anesthetized rat. 301 59
Synthetic human corticotropin-releasing factor (hCRF) stimulated
ACTH
secretion by human fetal pituitaries in superfusion and dispersed human fetal pituitary cells cultured on an extracellular matrix in static incubation from 14 to 23 wk gestational age. The action of hCRF in vitro was potentiated by arginine vasopressin (AVP) at all ages studied. 8-Br-cAMP induced a response similar to hCRF. The AVP effect on
ACTH
was synergistic with both CRF and 8-Br-cAMP. hCRF-mediated secretion of
ACTH
was noncompetitively inhibited by 24-h pretreatment, or by 3-h concomitant treatment, with dexamethasone. Neither
oxytocin
, catecholamines, prostaglandins, nor indomethacin exerted significant effects on
ACTH
secretion, either alone or in combination with hCRF or AVP during the gestational ages studied. These results support a physiologic role for CRF in the regulation of secretion by corticotropic cells as early as 14 wk gestation, by which time corticotropes and ability to secrete
ACTH
have been demonstrated.
...
PMID:Hypophysiotropic and neuromodulatory regulation of adrenocorticotropin in the human fetal pituitary gland. 301 39
Nitroprusside-induced hypotension evokes
ACTH
secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation. Portal plasma concentrations of neither arginine vasopressin nor
oxytocin
are significantly altered in this paradigm. Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and
oxytocin
at any corticosterone feedback dose tested. Resting irCRF levels are suppressed only at the highest corticosterone infusion rate, which resulted in systemic corticosterone levels of 40 micrograms/dl. Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl. These studies provide further evidence for a strong central component of the delayed feedback process which is mediated by modulation of irCRF release.
...
PMID:Inhibition of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation by delayed glucocorticoid feedback. 301 67
ACTH
secretion is primarily controlled by hypothalamic secretion of corticotropin releasing factor (CRF) into pituitary portal blood. However arginine vasopressin (AVP) and
oxytocin
(OT) can modulate the actions of CRF and at times may be important mediators of stress-induced
ACTH
secretion. The relative contributions of CRF, AVP, and OT to the control of
ACTH
secretion vary with different types of stress. In general, AVP stimulates
ACTH
secretion in all species studied. OT also stimulates
ACTH
release in rats but is inhibitory in primates. The involvement of AVP and OT in the control of
ACTH
secretion may have important implications for physiological and pathological conditions associated with activation of the hypothalamo--hypophysial--adrenal cortical axis.
...
PMID:Vasopressin and oxytocin: hypothalamic modulators of the stress response: a review. 301 20
<< Previous
1
2
3
4
5
6
7
8
9
10